Furthermore, Tamoxifen treated ER (+) breast cancers often increase BCL-2 and BCL-XL levels which leads to a decreased acute tumor response and ultimately to a long-term resistance to Tamoxifen [22]. The gene discussed is ESR1; the disease is breast carcinoma.